A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia.
J Pediatr Hematol Oncol
; 43(6): e788-e790, 2021 08 01.
Article
in English
| MEDLINE | ID: covidwho-811165
ABSTRACT
The literature regarding coronavirus disease of 2019 (COVID-19) infection in pediatrics indicates that children have less severe clinical presentations and lower mortality rates. There remains limited data regarding hematologic sequelae in pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Romiplostim has shown a platelet response in pediatric patients with chronic immune thrombocytopenic purpura, and eltrombopag is proven to increase platelet counts in patients with inherited thrombocytopenia. We review SARS-CoV-2-associated thrombocytopenia and present a pediatric patient with acute on chronic thrombocytopenia in the setting of COVID-19 with subsequent platelet recovery using romiplostim.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombocytopenia
/
Thrombopoietin
/
Recombinant Fusion Proteins
/
Receptors, Fc
/
SARS-CoV-2
/
COVID-19
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Child
/
Humans
/
Male
Language:
English
Journal:
J Pediatr Hematol Oncol
Journal subject:
Hematology
/
Neoplasms
/
Pediatrics
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS